Generic Tibofem ( Estradiol )

Buy Generic Tibofem (Estradiol) without prescription in Canada

In our Canadian pharmacy, you can buy Tibofem (Estradiol) without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Tibofem (estradiol) is a natural estrogen hormone used for the relief of moderate to severe vasomotor symptoms (hot flushes) and vulvovaginal atrophy associated with menopause, and for the prevention of postmenopausal osteoporosis when other therapies are not suitable. It works by replacing the estrogen that the ovaries stop producing after menopause, thereby rebalancing hormone levels, stabilising thermoregulation, preserving bone density, and restoring the health of vaginal tissues.

Usual adult dose: The recommended starting dose is 2.5 mg taken orally once daily, with or without food. Treatment is usually initiated at the lowest effective dose for the shortest duration consistent with treatment goals. In women with an intact uterus, a progestin must be added for at least 12 to 14 days of each cycle to reduce the risk of endometrial hyperplasia and cancer. In hysterectomized women, estrogen alone can be used continuously. The tablet should be swallowed whole with a glass of water, preferably at the same time each day.

Dosage form: Oral film‑coated tablet containing 2.5 mg of estradiol (as estradiol valerate or estradiol hemihydrate, depending on the international manufacturer).

Onset of action: Relief of menopausal hot flushes and night sweats is typically observed within 2 to 4 weeks of starting therapy, with maximum benefit achieved after 3 to 6 months of continuous treatment. Improvement in vaginal atrophy may take longer, often 6 to 12 months.

Duration of action: The elimination half‑life of estradiol is approximately 12 to 14 hours, but the clinical effects persist for 24 hours with once‑daily dosing. Steady‑state estrogen levels are maintained with regular daily intake. When treatment is discontinued, menopausal symptoms gradually return over days to weeks, and bone loss resumes.

Alcohol recommendation: Alcohol consumption should be limited during treatment with Tibofem. Heavy alcohol intake can increase circulating estrogen levels, potentially increasing the risk of estrogen‑related side effects and breast cancer. Moderate alcohol consumption (no more than one drink per day) is generally considered acceptable.

Most common side effects: Breast tenderness or enlargement, nausea, headache, fluid retention (bloating), weight changes, irregular vaginal bleeding or spotting (particularly during the first few months), and mood changes. These effects are often dose‑dependent and may diminish with continued use or dose reduction. Rare but serious risks include endometrial cancer (in women with an intact uterus who do not take a progestin), venous thromboembolism (blood clots), stroke, coronary heart disease, breast cancer, ovarian cancer, and gallbladder disease. The 2.5 mg dose is a moderately high dose of estradiol and may be associated with a higher incidence of estrogen‑related side effects than lower doses.

Would you like to try Tibofem (Estradiol) without a prescription?

General Information about Tibofem (Estradiol)

• INN (International Nonproprietary Name): Estradiol (as estradiol valerate or estradiol hemihydrate, depending on formulation).
• Brand names available in Canada: Tibofem® is not a marketed brand in Canada. Estradiol is available in Canada under the brand names Estrace® (estradiol hemihydrate tablets, 0.5 mg, 1 mg, 2 mg) and various generic estradiol tablets. Tibofem 2.5 mg is an internationally sourced product obtained by our pharmacy through the international supply chain for personal importation.
• ATC code: G03CA03 (estradiol; natural and semisynthetic estrogens, plain).
• Dosage forms and strengths: Oral film‑coated tablet: 2.5 mg estradiol (as estradiol valerate or hemihydrate). In Canada, approved estradiol tablets are 0.5 mg, 1 mg, and 2 mg. The 2.5 mg strength is available internationally.
• Manufacturers in Canada: None. Tibofem is not manufactured in Canada. Canadian‑approved estradiol tablets are manufactured by various generic companies. Tibofem is manufactured internationally and imported for personal use.
• Registration status in Canada: Not marketed in Canada. Tibofem has not been issued a Notice of Compliance by Health Canada and is not listed in the Drug Product Database. The active ingredient, estradiol, is approved in other strengths.
• OTC / Rx classification: Prescription only (Rx). A valid prescription from a licensed Canadian healthcare professional is required for personal importation.

Mechanism of Action and Pharmacology

Estradiol is the most potent naturally occurring estrogen and is chemically identical to the estrogen produced by the ovaries in premenopausal women. It exerts its effects by binding to estrogen receptors (ER‑α and ER‑β) located in many tissues, including the hypothalamus, bone, breast, endometrium, and vagina. In the hypothalamus, estrogen restores thermoregulatory stability, reducing the frequency and severity of hot flushes. In bone, it inhibits the activity of osteoclasts and reduces bone resorption, thereby preserving bone mineral density and lowering the risk of vertebral fractures. In the vaginal epithelium, it restores thickness, glycogen content, and lubrication, alleviating symptoms of vaginal atrophy such as dryness, itching, and dyspareunia. Estradiol also has favourable effects on lipid metabolism, increasing high‑density lipoprotein (HDL) cholesterol and decreasing low‑density lipoprotein (LDL) cholesterol. In women with an intact uterus, unopposed estrogen therapy stimulates endometrial proliferation and increases the risk of endometrial hyperplasia and cancer; therefore, a progestin must be added to oppose this effect. In hysterectomized women, estrogen alone is sufficient.

After oral administration, estradiol is well absorbed from the gastrointestinal tract. It undergoes extensive first‑pass hepatic metabolism, primarily to estrone and estriol. Estradiol is highly protein‑bound (to sex‑hormone‑binding globulin and albumin). The elimination half‑life of estradiol is approximately 12‑14 hours. Metabolites are excreted in the urine. The 2.5 mg dose provides a moderate to high level of estrogen replacement, suitable for women who have persistent symptoms on lower doses or who require higher bone protection.

Indications

• Vasomotor symptoms of menopause: For the relief of moderate to severe hot flushes (flashes) and night sweats associated with natural or surgical menopause.
• Vulvovaginal atrophy: For the treatment of moderate to severe symptoms of vulvar and vaginal atrophy (dryness, irritation, pain during intercourse) in postmenopausal women.
• Prevention of osteoporosis: For the prevention of postmenopausal osteoporosis in women with significant risk factors who are unable to take other osteoporosis therapies. The 2.5 mg dose provides bone‑sparing effects comparable to or greater than lower doses.
• Tibofem is not indicated for the treatment of cognitive decline, cardiovascular disease, or for use in premenopausal women, children, or men. It should be used for the shortest duration at the lowest effective dose consistent with treatment goals.

Important Warnings and Precautions

At‑risk groups

• Pregnancy: Tibofem is absolutely contraindicated during pregnancy. There is no known indication for estrogen therapy during pregnancy. If pregnancy occurs, the medication must be discontinued immediately. Women of childbearing potential should use effective non‑hormonal contraception.
• Breastfeeding: Estrogen therapy reduces the quantity and quality of breast milk. Small amounts of estrogen are excreted in breast milk. Tibofem should not be used during breastfeeding.
• Paediatrics (< 18 years): Safety and efficacy have not been established in children. Tibofem is not indicated for paediatric use.
• Elderly (> 65 years): Initiation of estrogen therapy in women older than 65 years should only be undertaken after careful individual assessment of the risks and benefits, as the absolute risks of stroke, venous thromboembolism, and dementia are higher in this age group. The lowest effective dose should be used.
• Endometrial cancer risk: Unopposed estrogen therapy increases the risk of endometrial hyperplasia and endometrial cancer. In women with an intact uterus, a progestin must be added for 12‑14 days per month to reduce this risk. Any unexplained vaginal bleeding should be investigated promptly.
• Venous thromboembolism (VTE): Estrogen therapy increases the risk of deep vein thrombosis and pulmonary embolism, particularly in the first year of use and in women with thrombophilia, obesity, or prolonged immobilisation. The risk with oral estrogen is higher than with transdermal preparations. Tibofem should be discontinued at least 4 weeks before major surgery or during prolonged immobility.
• Stroke and cardiovascular disease: Estrogen therapy is associated with an increased risk of ischaemic stroke. It should not be used for the prevention of cardiovascular disease. Women with pre‑existing cardiovascular disease should use estrogen with extreme caution.
• Breast cancer: Long‑term use of combined estrogen‑progestin therapy has been associated with an increased risk of breast cancer. The risk increases with duration of use. Estrogen‑alone therapy (in hysterectomized women) may also increase breast cancer risk, though to a lesser extent. All women should undergo regular breast examinations and mammography.
• Gallbladder disease: Estrogen therapy increases the risk of gallstone formation and cholecystitis.
• Hepatic impairment: Tibofem is contraindicated in patients with severe liver disease or a history of cholestatic jaundice. Use with caution in mild to moderate hepatic impairment; liver function tests should be monitored.
• Hypertriglyceridemia: Estrogen therapy can cause severe hypertriglyceridemia and pancreatitis in women with pre‑existing hypertriglyceridemia. Serum triglycerides should be monitored.
• Dementia: Estrogen therapy initiated in women over 65 has been associated with an increased risk of probable dementia. It is not recommended for the prevention of cognitive decline.
• Allergy: Do not take Tibofem if you have a known hypersensitivity to estradiol or any excipient in the tablet formulation.

Driving and alcohol

Tibofem is not known to impair the ability to drive or operate machinery. However, some patients may experience dizziness or fatigue, particularly at the start of therapy. Patients should ensure they are not adversely affected before driving. Alcohol consumption should be limited during treatment. Heavy alcohol intake can increase circulating estrogen levels, potentially increasing the risk of estrogen‑related side effects and breast cancer. Moderate alcohol consumption (no more than one drink per day) is generally acceptable.

Dosage Instructions

• Standard adult dose (postmenopausal women): 2.5 mg taken orally once daily, with or without food. For women with an intact uterus, a progestin (e.g., medroxyprogesterone acetate 5‑10 mg daily for 12‑14 days each month, or micronized progesterone 200 mg daily for 12‑14 days each month) must be added to prevent endometrial hyperplasia. Hysterectomized women can take estrogen alone continuously.
• Administration: Swallow the tablet whole with a glass of water. It may be taken at any time of day, but a consistent time (e.g., each morning) helps establish a routine. The tablet should not be crushed, chewed, or split.
• Missed dose: If a dose is missed, take it as soon as remembered on the same day. If it is close to the time of the next scheduled dose, skip the missed dose and resume the regular once‑daily schedule. Do not double the dose.
• Duration of therapy: Tibofem should be used for the shortest duration at the lowest effective dose consistent with treatment goals. The need for continued therapy should be reassessed periodically (e.g., every 6‑12 months). For osteoporosis prevention, long‑term therapy may be required, but the risks should be weighed against the benefits.
• Discontinuation: If Tibofem is to be stopped, the dose may be tapered gradually to minimise the return of menopausal symptoms. Abrupt discontinuation is not associated with a withdrawal syndrome but may result in rapid symptom recurrence.

Side Effects and Contraindications

• Very common side effects (≥ 10%): Breast tenderness or enlargement, and breakthrough uterine bleeding or spotting (especially during the first 3‑6 months of therapy).
• Common side effects (1‑10%): Nausea, bloating, weight gain, headache, dizziness, mood swings, depression, and leg cramps. These are more common at higher doses such as 2.5 mg and often subside with continued use or dose reduction.
• Serious adverse reactions: Endometrial hyperplasia and endometrial cancer (in women with an intact uterus taking unopposed estrogen); venous thromboembolism (deep vein thrombosis, pulmonary embolism); ischaemic stroke; myocardial infarction; breast cancer; ovarian cancer; gallbladder disease requiring surgery; probable dementia (in women initiating therapy after age 65); pancreatitis from severe hypertriglyceridemia; and cholestatic jaundice.
• Post‑marketing reports: Erythema multiforme, erythema nodosum, and anaphylaxis have been reported rarely.
• Contraindications: Known or suspected pregnancy; breastfeeding; undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen‑dependent neoplasia (e.g., endometrial cancer); active or past history of venous thromboembolism; thrombophilia; active or recent arterial thromboembolic disease (e.g., myocardial infarction, stroke); severe liver disease or history of cholestatic jaundice; known hypersensitivity to estradiol or any excipient.

Drug Interactions

• Enzyme‑inducing drugs (reduce estrogen efficacy): Rifampicin, rifabutin, carbamazepine, phenobarbital, phenytoin, primidone, oxcarbazepine, topiramate, griseofulvin, and St. John’s wort can increase the hepatic metabolism of estradiol and may reduce its therapeutic effect. A higher dose of estradiol or alternative non‑hormonal therapy may be required.
• CYP3A4 inhibitors (increase estrogen exposure): Ketoconazole, itraconazole, clarithromycin, ritonavir, and grapefruit juice may increase circulating estrogen levels. Monitoring for estrogen‑related side effects is recommended.
• Warfarin and other anticoagulants: Estrogen therapy may alter the metabolism of warfarin and affect prothrombin time. Close monitoring of the INR is advised when initiating or discontinuing estrogen.
• Thyroid hormone: Estrogen increases thyroid‑binding globulin, which may reduce free thyroid hormone levels. Women on levothyroxine may need a dose increase; thyroid function should be monitored.
• Other hormonal contraceptives: Concomitant use with other estrogen‑ or progestin‑containing contraceptives is not recommended, as it may increase estrogenic and progestogenic side effects.
• Alcohol: Heavy alcohol consumption may increase circulating estrogen levels. Limit alcohol to moderate amounts.

Practical Advice

• Administration: Take one tablet at approximately the same time each day, with or without food. Swallow whole with water. If you have an intact uterus, ensure you are also taking your prescribed progestin as directed. Do not skip the progestin component, as this protects the uterine lining.
• Monitoring: All women should have a complete medical history and physical examination, including a breast examination, pelvic examination, and blood pressure measurement, before starting therapy and at regular intervals during treatment. Mammography should be performed according to age‑appropriate screening guidelines. In women with an intact uterus, any unexplained or persistent vaginal bleeding requires prompt investigation, which may include endometrial biopsy. Liver function tests and serum triglycerides should be monitored in at‑risk patients. Bone mineral density should be monitored every 1‑2 years if Tibofem is used for osteoporosis prevention.
• Storage: Store at room temperature (15‑30 °C) in a dry place, protected from moisture and light. Keep the container tightly closed. Keep out of the reach and sight of children.
• Lifestyle: Tibofem is most effective when combined with a healthy lifestyle, including a balanced diet rich in calcium and vitamin D, regular weight‑bearing exercise, smoking cessation, and moderation of alcohol. Avoid prolonged immobilisation; when travelling, move legs periodically to reduce the risk of blood clots. If you are scheduled for surgery, inform your surgeon that you are taking estrogen therapy; the medication may need to be discontinued temporarily.
• Missed dose: If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and return to your regular schedule. Do not take a double dose.
• When to seek medical review: Stop Tibofem and contact your doctor immediately if you experience: signs of a blood clot (leg pain/swelling, sudden chest pain, coughing up blood, sudden shortness of breath); signs of a stroke (sudden severe headache, confusion, weakness on one side of the body, vision changes); signs of liver injury (jaundice, dark urine, right upper abdominal pain); a new breast lump; or unexplained heavy or prolonged vaginal bleeding. Seek emergency care for any of these symptoms.
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Lower‑dose oral estradiol: Estrace® (estradiol hemihydrate) in 0.5 mg, 1 mg, or 2 mg daily provides lower systemic estrogen exposure with a potentially more favourable safety profile. The 2.5 mg dose of Tibofem is higher than the standard starting doses, and women who achieve symptom relief on a lower dose should be maintained at that dose.
• Transdermal estradiol (patch, gel, spray): Transdermal estrogen bypasses first‑pass hepatic metabolism, reducing the risk of venous thromboembolism compared with oral estrogen. Patches (e.g., Estradot®, Climara®) and gels (e.g., Estrogel®) are approved in Canada and provide steady estrogen levels. They are preferred for women with hypertriglyceridemia or risk factors for VTE.
• Conjugated estrogens (Premarin®): A mixture of estrogens derived from pregnant mare’s urine, available in oral and vaginal formulations. It has a similar efficacy and risk profile to estradiol.
• Combined estrogen‑progestin products: Premplus® (conjugated estrogens plus medroxyprogesterone), Activelle® (estradiol plus norethindrone), and others provide both hormones in a single tablet for women with an intact uterus.
• Non‑hormonal therapies for hot flushes: Selective serotonin reuptake inhibitors (SSRIs) such as paroxetine (Paxil®) and serotonin‑norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine (Effexor®) can reduce vasomotor symptoms. Gabapentin (Neurontin®) is also effective for some women.
• Non‑pharmacological approaches: Lifestyle modifications including dressing in layers, keeping the bedroom cool, avoiding hot beverages and spicy foods, regular exercise, and stress reduction techniques can help manage mild hot flushes without medication.

Clinical Efficacy

Estradiol is the most physiologically relevant estrogen for hormone replacement therapy. Numerous randomised placebo‑controlled trials have demonstrated that oral estradiol effectively reduces the frequency and severity of hot flushes by approximately 75‑90%, with significant improvement within 2‑4 weeks. The 2.5 mg dose provides a robust estrogenic effect and is more effective for bone preservation than lower doses, with increases in bone mineral density of 3‑6% over 2 years at the lumbar spine. The Women’s Health Initiative (WHI) and other large prospective studies have established the risk‑benefit profile of estrogen therapy: unopposed estrogen reduces the risk of osteoporotic fractures but is associated with increased risks of stroke, venous thromboembolism, and, with long‑term use, breast cancer. The addition of a progestin for endometrial protection further modifies the risk profile. Current Canadian and international guidelines recommend using the lowest effective dose for the shortest possible duration, and individualising therapy based on age, time since menopause, and presence or absence of the uterus. The 2.5 mg dose is a moderately high dose and is generally reserved for women who do not achieve adequate symptom relief or bone protection on lower doses, after careful risk‑benefit assessment.

Important:

Tibofem (estradiol) is a prescription medication that should be used only under the supervision of a qualified healthcare professional. It carries serious risks, including an increased risk of endometrial cancer if used without a progestin in women with an intact uterus, and an increased risk of blood clots (venous thromboembolism), stroke, and breast cancer. You must not take Tibofem if you are pregnant, breastfeeding, or have a history of blood clots, liver disease, or hormone‑dependent cancers. Seek immediate medical attention if you develop symptoms of a blood clot, stroke, or liver problems. This product is not marketed in Canada and is imported for personal use under a valid prescription. Use the lowest effective dose for the shortest possible duration. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Tibofem - Shipping across Canada